The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors

Hsiao Mei Hsu; Hsin I. Tsai; Wei Chen Lee; Chih Chi Wang; Ming Chin Yu; Shi Ming Lin; Chun Yen Lin; Chi Huan Wu; Chao Wei Lee

doi:10.2147/JHC.S433598

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors

Hsiao Mei Hsu, Hsin I. Tsai, Wei Chen Lee, Chih Chi Wang, Ming Chin Yu, Shi Ming Lin, Chun Yen Lin, Chi Huan Wu, Chao Wei Lee^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

3 Scopus citations

Abstract

Surgical resection remains one of the most effective curative therapies for HCC. However, the majority of patients have advanced unresectable diseases upon presentation. It is of paramount importance to raise the resectability of patients with HCC. The remarkable objective response rate reported by Phase III IMbrave150 trial has led to the concept of “Atezo/Bev followed by curative conversion (ABC conversion)” for initially unresectable HCC. With this revolutionary treatment strategy, the concept of surgical resection for HCC should be amended. The current opinion illustrated three extended surgical concepts, which could be integrated into clinical practice in the era of immune checkpoint inhibitors (ICI).

Original language	English
Pages (from-to)	1873-1880
Number of pages	8
Journal	Journal of Hepatocellular Carcinoma
Volume	10
DOIs	https://doi.org/10.2147/JHC.S433598
State	Published - 2023

Bibliographical note

Keywords

hepatocellular carcinoma
immune checkpoint inhibitors
immunotherapy
liver resection
surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/JHC.S433598

Cite this

@article{4e4ea0214a3e475b8b4633f7882db843,

title = "The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors",

abstract = "Surgical resection remains one of the most effective curative therapies for HCC. However, the majority of patients have advanced unresectable diseases upon presentation. It is of paramount importance to raise the resectability of patients with HCC. The remarkable objective response rate reported by Phase III IMbrave150 trial has led to the concept of “Atezo/Bev followed by curative conversion (ABC conversion)” for initially unresectable HCC. With this revolutionary treatment strategy, the concept of surgical resection for HCC should be amended. The current opinion illustrated three extended surgical concepts, which could be integrated into clinical practice in the era of immune checkpoint inhibitors (ICI).",

keywords = "hepatocellular carcinoma, immune checkpoint inhibitors, immunotherapy, liver resection, surgery",

author = "Hsu, \{Hsiao Mei\} and Tsai, \{Hsin I.\} and Lee, \{Wei Chen\} and Wang, \{Chih Chi\} and Yu, \{Ming Chin\} and Lin, \{Shi Ming\} and Lin, \{Chun Yen\} and Wu, \{Chi Huan\} and Lee, \{Chao Wei\}",

note = "{\textcopyright} 2023 Hsu et al.",

year = "2023",

doi = "10.2147/JHC.S433598",

language = "英语",

volume = "10",

pages = "1873--1880",

journal = "Journal of Hepatocellular Carcinoma",

issn = "2253-5969",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors

AU - Hsu, Hsiao Mei

AU - Tsai, Hsin I.

AU - Lee, Wei Chen

AU - Wang, Chih Chi

AU - Yu, Ming Chin

AU - Lin, Shi Ming

AU - Lin, Chun Yen

AU - Wu, Chi Huan

AU - Lee, Chao Wei

PY - 2023

Y1 - 2023

N2 - Surgical resection remains one of the most effective curative therapies for HCC. However, the majority of patients have advanced unresectable diseases upon presentation. It is of paramount importance to raise the resectability of patients with HCC. The remarkable objective response rate reported by Phase III IMbrave150 trial has led to the concept of “Atezo/Bev followed by curative conversion (ABC conversion)” for initially unresectable HCC. With this revolutionary treatment strategy, the concept of surgical resection for HCC should be amended. The current opinion illustrated three extended surgical concepts, which could be integrated into clinical practice in the era of immune checkpoint inhibitors (ICI).

AB - Surgical resection remains one of the most effective curative therapies for HCC. However, the majority of patients have advanced unresectable diseases upon presentation. It is of paramount importance to raise the resectability of patients with HCC. The remarkable objective response rate reported by Phase III IMbrave150 trial has led to the concept of “Atezo/Bev followed by curative conversion (ABC conversion)” for initially unresectable HCC. With this revolutionary treatment strategy, the concept of surgical resection for HCC should be amended. The current opinion illustrated three extended surgical concepts, which could be integrated into clinical practice in the era of immune checkpoint inhibitors (ICI).

KW - hepatocellular carcinoma

KW - immune checkpoint inhibitors

KW - immunotherapy

KW - liver resection

KW - surgery

UR - https://www.scopus.com/pages/publications/85174907005

U2 - 10.2147/JHC.S433598

DO - 10.2147/JHC.S433598

M3 - 文章

C2 - 37901716

AN - SCOPUS:85174907005

SN - 2253-5969

VL - 10

SP - 1873

EP - 1880

JO - Journal of Hepatocellular Carcinoma

JF - Journal of Hepatocellular Carcinoma

ER -

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this